Molecular genetic analysis of ovarian serous cystadenomas

Eric J. Cheng, Robert J Kurman, Menglin Wang, Robert Oldt, Brant G. Wang, David M. Berman, Ie Ming Shih

Research output: Contribution to journalArticle

Abstract

Ovarian serous cystadenomas are common ovarian lesions that may be precursors of serous borderline tumors, which can in turn progress to low-grade serous carcinomas. It has been shown that low-grade serous carcinoma and serous borderline tumors are characterized by frequent mutations in BRAF or KRAS genes, but the mutational status of these genes in serous cystadenomas and the clonal nature of serous cystadenomas have not been fully investigated. We isolated cyst-lining epithelium from 30 consecutive serous cystadenomas, and analyzed their BRAF and KRAS mutational status. Wild-type sequences of BRAF and KRAS were detected in all specimens. Using the human androgen receptor gene as a polymorphic marker, we also examined the clonal status of epithelial cells in all of the serous cystadenomas. Four of 29 (14%) informative specimens were monoclonal based on the methylation pattern. These monoclonal cystadenomas were significantly (P8 cm) than the nonclonal cystadenomas. These data indicate that serous cystadenomas do not contain mutations in either BRAF or KRAS genes and that most serous cystadenomas are polyclonal. Accordingly, it appears that serous cystadenomas develop as a hyperplastic expansion from epithelial inclusions with a clonal/neoplastic transformation occurring in a subset of them.

Original languageEnglish (US)
Pages (from-to)778-784
Number of pages7
JournalLaboratory Investigation
Volume84
Issue number6
DOIs
StatePublished - Jun 2004

Fingerprint

Serous Cystadenoma
Molecular Biology
Cystadenoma
Genes
Carcinoma
Mutation
Methylation
Cysts
Neoplasms
Epithelium
Epithelial Cells

Keywords

  • BRAF
  • Clonality
  • HUMARA
  • Inactivation
  • KRAS
  • Serous cystadenomas
  • X-chromosome

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Molecular genetic analysis of ovarian serous cystadenomas. / Cheng, Eric J.; Kurman, Robert J; Wang, Menglin; Oldt, Robert; Wang, Brant G.; Berman, David M.; Shih, Ie Ming.

In: Laboratory Investigation, Vol. 84, No. 6, 06.2004, p. 778-784.

Research output: Contribution to journalArticle

Cheng, Eric J. ; Kurman, Robert J ; Wang, Menglin ; Oldt, Robert ; Wang, Brant G. ; Berman, David M. ; Shih, Ie Ming. / Molecular genetic analysis of ovarian serous cystadenomas. In: Laboratory Investigation. 2004 ; Vol. 84, No. 6. pp. 778-784.
@article{a3cd497e7f074474b7b23cb7a27d7376,
title = "Molecular genetic analysis of ovarian serous cystadenomas",
abstract = "Ovarian serous cystadenomas are common ovarian lesions that may be precursors of serous borderline tumors, which can in turn progress to low-grade serous carcinomas. It has been shown that low-grade serous carcinoma and serous borderline tumors are characterized by frequent mutations in BRAF or KRAS genes, but the mutational status of these genes in serous cystadenomas and the clonal nature of serous cystadenomas have not been fully investigated. We isolated cyst-lining epithelium from 30 consecutive serous cystadenomas, and analyzed their BRAF and KRAS mutational status. Wild-type sequences of BRAF and KRAS were detected in all specimens. Using the human androgen receptor gene as a polymorphic marker, we also examined the clonal status of epithelial cells in all of the serous cystadenomas. Four of 29 (14{\%}) informative specimens were monoclonal based on the methylation pattern. These monoclonal cystadenomas were significantly (P8 cm) than the nonclonal cystadenomas. These data indicate that serous cystadenomas do not contain mutations in either BRAF or KRAS genes and that most serous cystadenomas are polyclonal. Accordingly, it appears that serous cystadenomas develop as a hyperplastic expansion from epithelial inclusions with a clonal/neoplastic transformation occurring in a subset of them.",
keywords = "BRAF, Clonality, HUMARA, Inactivation, KRAS, Serous cystadenomas, X-chromosome",
author = "Cheng, {Eric J.} and Kurman, {Robert J} and Menglin Wang and Robert Oldt and Wang, {Brant G.} and Berman, {David M.} and Shih, {Ie Ming}",
year = "2004",
month = "6",
doi = "10.1038/labinvest.3700103",
language = "English (US)",
volume = "84",
pages = "778--784",
journal = "Laboratory Investigation",
issn = "0023-6837",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Molecular genetic analysis of ovarian serous cystadenomas

AU - Cheng, Eric J.

AU - Kurman, Robert J

AU - Wang, Menglin

AU - Oldt, Robert

AU - Wang, Brant G.

AU - Berman, David M.

AU - Shih, Ie Ming

PY - 2004/6

Y1 - 2004/6

N2 - Ovarian serous cystadenomas are common ovarian lesions that may be precursors of serous borderline tumors, which can in turn progress to low-grade serous carcinomas. It has been shown that low-grade serous carcinoma and serous borderline tumors are characterized by frequent mutations in BRAF or KRAS genes, but the mutational status of these genes in serous cystadenomas and the clonal nature of serous cystadenomas have not been fully investigated. We isolated cyst-lining epithelium from 30 consecutive serous cystadenomas, and analyzed their BRAF and KRAS mutational status. Wild-type sequences of BRAF and KRAS were detected in all specimens. Using the human androgen receptor gene as a polymorphic marker, we also examined the clonal status of epithelial cells in all of the serous cystadenomas. Four of 29 (14%) informative specimens were monoclonal based on the methylation pattern. These monoclonal cystadenomas were significantly (P8 cm) than the nonclonal cystadenomas. These data indicate that serous cystadenomas do not contain mutations in either BRAF or KRAS genes and that most serous cystadenomas are polyclonal. Accordingly, it appears that serous cystadenomas develop as a hyperplastic expansion from epithelial inclusions with a clonal/neoplastic transformation occurring in a subset of them.

AB - Ovarian serous cystadenomas are common ovarian lesions that may be precursors of serous borderline tumors, which can in turn progress to low-grade serous carcinomas. It has been shown that low-grade serous carcinoma and serous borderline tumors are characterized by frequent mutations in BRAF or KRAS genes, but the mutational status of these genes in serous cystadenomas and the clonal nature of serous cystadenomas have not been fully investigated. We isolated cyst-lining epithelium from 30 consecutive serous cystadenomas, and analyzed their BRAF and KRAS mutational status. Wild-type sequences of BRAF and KRAS were detected in all specimens. Using the human androgen receptor gene as a polymorphic marker, we also examined the clonal status of epithelial cells in all of the serous cystadenomas. Four of 29 (14%) informative specimens were monoclonal based on the methylation pattern. These monoclonal cystadenomas were significantly (P8 cm) than the nonclonal cystadenomas. These data indicate that serous cystadenomas do not contain mutations in either BRAF or KRAS genes and that most serous cystadenomas are polyclonal. Accordingly, it appears that serous cystadenomas develop as a hyperplastic expansion from epithelial inclusions with a clonal/neoplastic transformation occurring in a subset of them.

KW - BRAF

KW - Clonality

KW - HUMARA

KW - Inactivation

KW - KRAS

KW - Serous cystadenomas

KW - X-chromosome

UR - http://www.scopus.com/inward/record.url?scp=1942446851&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1942446851&partnerID=8YFLogxK

U2 - 10.1038/labinvest.3700103

DO - 10.1038/labinvest.3700103

M3 - Article

VL - 84

SP - 778

EP - 784

JO - Laboratory Investigation

JF - Laboratory Investigation

SN - 0023-6837

IS - 6

ER -